Wells Fargo’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-185
| Closed | -$130 | – | 7760 |
|
|
2023
Q1 | $130 | Buy |
185
+3
| +2% | +$3 | ﹤0.01% | 6882 |
|
|
2022
Q4 | $164 | Buy |
182
+48
| +36% | +$139 | ﹤0.01% | 6687 |
|
|
2022
Q3 | $1K | Buy |
134
+16
| +14% | +$91 | ﹤0.01% | 6546 |
|
|
2022
Q2 | $0 | Buy |
118
+9
| +8% | +$32 | ﹤0.01% | 7847 |
|
|
2022
Q1 | $0 | Buy |
109
+1
| +0.9% | +$5 | ﹤0.01% | 8168 |
|
|
2021
Q4 | $0 | Hold |
108
| – | – | ﹤0.01% | 8096 |
|
|
2021
Q3 | $1K | Buy |
108
+57
| +112% | +$302 | ﹤0.01% | 6862 |
|
|
2021
Q2 | $0 | Sell |
51
-3,234
| -98% | -$17.4K | ﹤0.01% | 7703 |
|
|
2021
Q1 | $19K | Sell |
3,285
-4,382
| -57% | -$26.5K | ﹤0.01% | 6182 |
|
|
2020
Q4 | $35K | Buy |
7,667
+2,278
| +42% | +$9.82K | ﹤0.01% | 5707 |
|
|
2020
Q3 | $21K | Sell |
5,389
-2,418
| -31% | -$48.6K | ﹤0.01% | 5746 |
|
|
2020
Q2 | $225K | Buy |
7,807
+4,568
| +141% | +$106K | ﹤0.01% | 4836 |
|
|
2020
Q1 | $70K | Buy |
3,239
+2,881
| +805% | +$65.4K | ﹤0.01% | 5226 |
|
|
2019
Q4 | $7K | Buy |
+358
| New | +$5.09K | ﹤0.01% | 5987 |
|
Wells Fargo's STSA Position: Q2 2023 in Review
Wells Fargo sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 185 shares — an estimated $130 sold.
Wells Fargo first reported a position in STSA in Q4 2019 and held it in 14 quarters. The position peaked at $225K in Q2 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.
- Wells Fargo reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Wells Fargo sold 185 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $130.
- Wells Fargo first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
- Wells Fargo's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $225K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.
Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.